Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
about
Guanylate cyclase stimulators for pulmonary hypertensionPulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and managementTargeting heart failure with preserved ejection fraction: current status and future prospectsBreakthrough in heart failure with preserved ejection fraction: are we there yet?Left ventricular heart failure and pulmonary hypertensionCardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionExercise intolerance in heart failure with preserved ejection fraction: more than a heart problemClinical Phenotypes in Heart Failure With Preserved Ejection FractionAdvances in the pathophysiology and treatment of heart failure with preserved ejection fractionRiociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.Heart failure with preserved ejection fraction in the elderly: scope of the problem.Management of pulmonary hypertension due to heart failure with preserved ejection fraction.Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.Controversies in pulmonary hypertension due to left heart diseaseAdvanced imaging tools rather than hemodynamics should be the primary approach for diagnosing, following, and managing pulmonary arterial hypertension.Riociguat: a novel new drug for treatment of pulmonary hypertension.Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival.Riociguat for the treatment of pulmonary hypertension.Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.Heart Failure with Preserved Ejection Fraction in Older Adults.Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction.Targets for Heart Failure With Preserved Ejection Fraction.Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease.Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?Treatment and Prognosis of Pulmonary Hypertension in the Left Ventricular Assist Device Patient.Riociguat for the treatment of pulmonary hypertension: a safety evaluation.Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation.Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction.Treatment of pulmonary hypertension with left heart disease: a concise review.Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
P2860
Q26470534-1F2206EA-5819-41EB-81F0-0032DFD972EAQ26750994-CE0F0552-DFAB-4BEC-8EF4-AAD8A7F4704BQ26752956-D70F4975-83C2-407B-8952-5E29D5169311Q26771999-419525F1-C52E-43E7-BA76-863DD3A32A56Q26778341-24DD67AA-32FD-4926-99E4-DF2B69108E57Q26853363-B43058B0-B7B3-4416-B09A-9EEE690C3079Q26991985-3C38E3A4-D8DE-4C4A-AD03-F6662C28BBEEQ28073079-FA0B406A-796C-4C54-BF5E-DCB477A87E84Q33565707-83EE7419-259F-48FB-ABE6-0CD2D8CC57AFQ33596457-712113DE-6838-4230-8AC0-2D7690736138Q34375466-2882C73C-297C-4B35-A6AF-1E4893296429Q35075847-D167E09B-DAA7-4F4F-84AA-74CBAE2846E7Q37058596-145C8F12-7594-406D-B415-2A9C9C63CF1AQ37075193-D8719A0D-3650-46ED-86B9-4E81D1EB1188Q37510689-5DAF6D4C-B4A0-4A0E-A5FD-7F5FF1145CAAQ37633991-0592329B-BBD2-4069-868A-29CC06ABBCE7Q38260650-DD225B53-70C9-4FDA-9A7A-BA9B20B526B0Q38261197-27864B09-C6E8-40F5-88BA-3DC2FF4C78DBQ38364200-BDF61D03-CA4C-4CC8-A7D8-CA6A36FAC8F8Q38404334-ADC2FCEA-C817-400B-8595-3A1DF3EA1C1EQ38502798-C5128B6D-EE76-44EE-BBBD-E6D8C8C9B13DQ38548379-47276F86-FB37-411E-A405-03BACE6006B8Q38645382-C8F42B10-EF41-45AC-9C50-65C24FD0B7AEQ38665806-B78BEC00-C157-4E07-967E-CBFC64D7BD42Q38672337-889A3B34-1F9A-491D-B3D2-DA14AD20F5B2Q38682382-0A31B643-7782-44D6-89B5-80967FC36DE3Q38688194-28AC5A4F-69BB-4601-9ED2-AD2055F02E93Q38737284-9DF1A613-1473-4EC3-8DB7-C4CF9856ED1DQ38743215-8AAAEC0E-1C8C-4BDE-9392-2011E2F46526Q38764956-96A94DA5-639D-4108-BD6E-0EE9BDD9B9EBQ38818606-0424A562-DFF6-4ACD-96EE-D160E87E3BD9Q38848544-4DADEE97-FFE3-4583-AD08-1552AB36696DQ38983098-6E7B1D16-4665-4534-A6E7-2E9B9952A50DQ39209626-1E91D154-E7DE-4E20-BD61-F7F2C5CE7DC5Q40722411-9F707022-D90B-44D5-B544-CE7FCDD9E9A1Q41302280-011768C7-D212-4165-830F-460EEDE7CD48Q42143771-CDA383A6-5398-4DBD-B912-838346AAAE3BQ42393093-AF5F21DC-7CEA-43AA-83E7-3A3588F5C040Q47156390-65168D0A-049B-4BEF-BF2E-01522E6B26ABQ47584698-6D11774B-7F0C-4FD5-8449-7CDAC32A303F
P2860
Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Acute hemodynamic effects of r ...... controlled, single-dose study.
@ast
Acute hemodynamic effects of r ...... controlled, single-dose study.
@en
Acute hemodynamic effects of r ...... controlled, single-dose study.
@nl
type
label
Acute hemodynamic effects of r ...... controlled, single-dose study.
@ast
Acute hemodynamic effects of r ...... controlled, single-dose study.
@en
Acute hemodynamic effects of r ...... controlled, single-dose study.
@nl
prefLabel
Acute hemodynamic effects of r ...... controlled, single-dose study.
@ast
Acute hemodynamic effects of r ...... controlled, single-dose study.
@en
Acute hemodynamic effects of r ...... controlled, single-dose study.
@nl
P2093
P2860
P921
P356
P1433
P1476
Acute hemodynamic effects of r ...... controlled, single-dose study.
@en
P2093
Andja Bojic
Caroline Tufaro
Carolyn S P Lam
Diana Bonderman
Ingrid Pretsch
Irene M Lang
Lothar Roessig
Michael Ochan Kilama
Pavel Jansa
Regina Steringer-Mascherbauer
P2860
P304
P356
10.1378/CHEST.14-0106
P407
P577
2014-11-01T00:00:00Z